Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide for hormone-refractory prostate cancer

Japanese Journal of Clinical Oncology

Volumn 41, Issue 2, 2011, Pages 253-259

  Hatano, Koji ^a   Nonomura, Norio ^a   Nishimura, Kazuo ^b   Kawashima, Atsunari ^a   Mukai, Masatoshi ^a   Nagahara, Akira ^a   Nakai, Yasutomo ^a   Nakayama, Masashi ^a   Takayama, Hitoshi ^a   Tsujimura, Akira ^a   Okuyama, Akihiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Chemotherapy cyclophosphamide; Dexamethasone; Hormone refractory prostate cancer; UFT

Indexed keywords

ANTIANDROGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; PROSTATE SPECIFIC ANTIGEN; UFT;

ADULT; AGED; ALOPECIA; ANOREXIA; ANTIANDROGEN THERAPY; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DRUG ERUPTION; DRUG RESPONSE; FATIGUE; FEMALE; HEMATURIA; HUMAN; HYPERCHOLESTEROLEMIA; LOW DRUG DOSE; LYMPH NODE METASTASIS; MALE; NEUTROPENIA; PERIPHERAL EDEMA; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DRUG TOXICITY; HUMANS; JAPAN; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TEGAFUR; URACIL;

EID: 79251626392     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq178     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24.
3. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-42.
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
6. Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 1995;76:96-100.
7. Nishimura K, Nonomura N, Yasunaga Y, Takaha N, Inoue H, Sugao H, et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 2000;89:2570-6.
8. Saika T, Kusaka N, Tsushima T, Yamato T, Ohashi T, Suyama B, et al. Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients. Int J Urol 2001;8:290-4.
9. Morioka M, Kobayashi T, Furukawa Y, Jo Y, Shinkai M, Matsuki T, et al. Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone. Urol Int 2002;68:10-5.
10. Akakura K, Suzuki H, Ueda T, Komiya A, Ichikawa T, Igarashi T, et al. Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6. Prostate 2003;56:106-9.
11. Venkitaraman R, Thomas K, Huddart RA, Horwich A, Dearnaley DP, Parker CC. Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int 2007;101:440-3.
12. Khandwala HM, Vassilopoulou-Sellin R, Logethetis CJ, Friend KE. Corticosteroid-induced inhibition of adrenal androgen production in selected patients with prostate cancer. Endocr Pract 2001;7:11-5.
13. Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T, et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 2001;93:1739-46.
14. Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 2006;12:3003-9.
15. Yano A, Fujii Y, Iwai A, Kawakami S, Kageyama Y, Kihara K. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res 2006;12:6012-7.
16. Miyake H, Hara I, Yamazaki H, Eto H. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer. Oncol Rep 2005;14:673-6.
17. Bhandari MS, Pienta KJ, Fardig J, Olson K, Smith DC. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma. Cancer 2006;106:1715-21.
18. Nicolini A, Mancini P, Ferrari P, Anselmi L, Tartarelli G, Bonazzi V, et al. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed Pharmacother 2004;58:447-50.
19. Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 2007;177:2136-40.
20. Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003;98:1643-8.
21. Nelius T, Klatte T, de Riese W, Haynes A, Filleur S. Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol 2010;27:363-7.
22. Nishimura K, Nonomura N, Ono Y, Nozawa M, Fukui T, Harada Y, et al. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer. Oncology 2001;60:49-54.
23. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59.
24. Weitzman AL, Shelton G, Zuech N, Owen CE, Judge T, Benson M, et al. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol 2000;163:834-7.
25. Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 1985;3:1013-21.
26. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985;3:827-41.
27. Daliani DD, Assikis V, Tu SM, Papandreou CN, Pagliaro LC, Holtkamp T, et al. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer 2003;97:561-7.
28. Hellerstedt B, Pienta KJ, Redman BG, Esper P, Dunn R, Fardig J, et al. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer 2003;98:1603-10.
29. Di Lorenzo G, Autorino R, De Laurentiis M, Forestieri V, Romano C, Prudente A, et al. Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. Cancer Biol Ther 2007;6:313-7.
30. Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 2009;15: 4954-62.
31. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731-5.
32. Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S, et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 2005;65:7045-51.
33. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, Jr, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006;98:516-21.